A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI

Update Il y a 2 ans
Reference: NCT00299000

Woman and Man


The purpose of the study is to evaluate the safety and efficacy of two dose levels of Naglazyme in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.

Inclusion criteria

  • Mucopolysaccharidosis VI ,Maroteaux Lamy Syndrome